Search hospitals > Ontario > TORONTO
Novartis Investigative Site
Claim this profileTORONTO, Ontario M5G 2M9
Global Leader in Breast Cancer
Global Leader in Skin Cancer
Conducts research for T-Lymphoblastic Leukemia/Lymphoma
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
222 reported clinical trials
0 medical researchers
Summary
Novartis Investigative Site is a medical facility located in TORONTO, Ontario. This center is recognized for care of Breast Cancer, Skin Cancer, T-Lymphoblastic Leukemia/Lymphoma, Lung Cancer, Non-Small Cell Lung Cancer and other specialties. Novartis Investigative Site is involved with conducting 222 clinical trials across 235 conditions. There are 0 research doctors associated with this hospital, such as .Area of expertise
1Breast Cancer
Global LeaderStage IV
Stage III
HER2 negative
2Skin Cancer
Global LeaderStage IV
BRAF positive
PD-L1 positive
Top PIs
Clinical Trials running at Novartis Investigative Site
Breast Cancer
Prostate Cancer
Skin Cancer
Lupus
Colorectal Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Lymphoma
Follicular Lymphoma
Acute Lymphoblastic Leukemia
[177Lu]Lu-NeoB + Capecitabine
for Metastatic Breast Cancer
In the phase I part, to determine the recommended doses (RD) and dosing regimens of \[177Lu\]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibitor. In the phase II part, to evaluate the preliminary anti-tumor activity of two different doses/regimens of \[177Lu\]Lu-NeoB in combination with capecitabine (dose optimization).
Recruiting1 award Phase 1 & 25 criteria
Radioactive Drugs
for Breast Cancer
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC) and colorectal cancer (CRC).
Recruiting1 award Phase 15 criteria
ECI830 + Ribociclib + Fulvestrant
for Breast Cancer
Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.
Recruiting1 award Phase 1 & 25 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Novartis Investigative Site?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.